In Canadian patients with early rheumatoid arthritis, hypertension affected nearly half of the cohort within 5 years - with a striking 34% of males developing new-onset hypertension compared to 21% of females - despite comparable blood pressure rates to the general population at diagnosis.
New study finds PROMs like HAQ-DI and VAS pain can screen for active psoriatic arthritis with 96% sensitivity, hinting at powerful remote monitoring potential for RA and PsA.
A recent study reveals significant improvements in knee muscle strength and pain reduction for end-stage knee osteoarthritis patients through a unique combination therapy.
New single-cell analysis of 987,743 cells from 216 gut biopsies identifies distinct cellular signatures associated with adalimumab response in IBD patients, including baseline differences in epithelial and myeloid cell populations.
Known placebo injections reduced chronic back pain intensity for one month and showed lasting benefits for mood and sleep through one year, while fMRI revealed increased connectivity between the ventromedial prefrontal cortex and pain-modulating brainstem regions.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A study reveals that while Notch signaling drives early RA pathology through neovascularization, anti-TNF therapy specifically reduced JAG1/2 and DLL1/4 transcription in synovial tissue myeloid cells, but only in good responders (ΔDAS28 >1.2 with DAS28 ≤3.2 at 12 weeks).
A recent study in JAMA Internal Medicine revealed that acupuncture significantly reduced chronic sciatica pain compared to sham acupuncture, with lasting benefits of up to 52 weeks.
An experimental long-acting steroid has shown promising results in providing long-lasting pain relief for knee osteoarthritis, with minimal side effects. Eupraxia Pharmaceuticals plans to conduct a larger Phase III trial for this innovative treatment. (Source: The Lancet Rheumatology)